Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | SLC18A3 | Q16572 | 3/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7343176 | 0.92 | MEN1 (0.45) | TDP1CYP2D6MEN1KMT2ALMNA | |
| SCHEMBL3076098 | 0.92 | — | — | |
| SCHEMBL495718 | 0.92 | MEN1 (0.45) | TDP1CYP2D6MEN1KMT2ALMNA | |
| SCHEMBL14393808 | 0.92 | MEN1 (0.45) | TDP1CYP2D6MEN1KMT2ALMNA | |
| SCHEMBL6909004 | 0.92 | MEN1 (0.45) | TDP1CYP2D6MEN1KMT2ALMNA | |
| SCHEMBL18821982 | 0.92 | — | — | |
| SCHEMBL11472496 | 0.92 | MEN1 (0.45) | TDP1CYP2D6MEN1KMT2ALMNA | |
| SCHEMBL20063736 | 0.90 | TDP1 (0.43) | TDP1CYP2D6MEN1KMT2ALMNA | |
| SCHEMBL1697382 | 0.90 | TDP1 (0.48) | TDP1CYP2D6MEN1KMT2ALMNA | |
| SCHEMBL20752154 | 0.90 | TDP1 (0.48) | TDP1CYP2D6MEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2318408-B1 | TRI-CYCLIC PYRAZOLOPYRIDINE KINASE INHIBITORS | VERTEX PHARMA (US) | 2016-02-17 | — | — | EP | claimed |
| US-9193722-B2 | Tri-cyclic pyrazolopyridine kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-11-24 | — | — | US | claimed |
| US-9137973-B2 | Pyrazolopyridine kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-09-22 | — | — | US | claimed |
| EP-2778155-A1 | 2-aminopyridine derivatives useful as kinase inhibitors | Vertex Pharmaceuticals Incorporated (US) | 2014-09-17 | — | — | EP | claimed |
| US-8809335-B2 | Pyrazolopyrimidine kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-19 | — | — | US | claimed |
| US-20140221334-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-07 | — | — | US | claimed |
| US-8569337-B2 | Tri-cyclic pyrazolopyridine kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-10-29 | — | — | US | claimed |
| EP-2328896-B1 | TRI-CYCLIC PYRAZOLOPYRIDINE KINASE INHIBITORS | VERTEX PHARMA (US) | 2013-10-23 | — | — | EP | claimed |
| US-8563576-B2 | Tri-cyclic pyrazolopyridine kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-10-22 | — | — | US | claimed |
| US-20130252939-A1 | TRI-CYCLIC PYRAZOLOPYRIDINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-09-26 | — | — | US | claimed |
| EP-2318407-A1 | PYRAZOLOPYRIDINE KINASE INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 2011-05-11 | — | — | EP | claimed |
| EP-2318408-A2 | TRI-CYCLIC PYRAZOLOPYRIDINE KINASE INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 2011-05-11 | — | — | EP | claimed |
| US-20110077237-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-31 | — | — | US | claimed |
| WO-2010011772-A2 | TRI-CYCLIC PYRAZOLOPYRIDINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-01-28 | — | — | WO | claimed |
| WO-2010011756-A1 | PYRAZOLOPYRIDINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-01-28 | — | — | WO | claimed |
| WO-2010011762-A1 | PYRAZOLOPYRIDINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-01-28 | — | — | WO | claimed |
| WO-2010011768-A1 | TRI-CYCLIC PYRAZOLOPYRIDINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-01-28 | — | — | WO | claimed |
| EP-2121613-A2 | 2-AMINOPYRIDINE DERIVATIVES USEFUL AS KINASE INHIBITORS | Vertex Pharmaceuticals, Inc. (US) | 2009-11-25 | — | — | EP | claimed |
| US-20090124602-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-05-14 | — | — | US | claimed |
| WO-2008094992-A2 | 2-AMINOPYRIDINE DERIVATIVES USEFUL AS KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-08-07 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221334-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K6 | TDP1 768/4885CYP2D6 3113/4885MEN1 1427/4885 |
| US-20130252939-A1 | TRI-CYCLIC PYRAZOLOPYRIDINE KINASE INHIBITORS | MAP3K20, MAP3K5, PRKACA | TDP1 577/4885CYP2D6 2454/4885MEN1 2222/4885 |
| US-20090124602-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K6 | TDP1 768/4885CYP2D6 3113/4885MEN1 1427/4885 |
| US-20110077237-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K6 | TDP1 768/4885CYP2D6 3113/4885MEN1 1427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.